Showing results (271-280 of 297) with videos related to
Sort By:
Pageof 30
Journal for Immunotherapy of Cancer|October 4, 2024
Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trialBixia Tang, Yu Chen, Yu Jiang, et al.Journal of Translational Medicine|March 10, 2012
De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancerXiwei Wu, George Somlo, Yang Yu, et al.European Journal of Cancer (Oxford, England : 1990)|March 13, 2024
A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanomaXiaoting Wei, Zhengyun Zou, Weizhen Zhang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2026
Trastuzumab Rezetecan in Human Epidermal Growth Factor Receptor 2-Expressing Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: A Multicenter, Open-Label, Phase I TrialTianshu Liu, Suxia Luo, Xianglin Yuan, et al.Journal of Gastrointestinal Oncology|September 12, 2022
Safety and effectiveness of apatinib in elderly patients with metastatic gastric cancer: a sub-analysis from the large-scale, prospective observational study of apatinib for gastric cancer treatment in a real-world clinical setting (AHEAD-G202)Xiang Wang, Diansheng Zhong, Junping Zhang, et al.Clinical Lung Cancer|August 22, 2022
A Phase IB Trial of Autologous Cytokine-Induced Killer Cells in Combination with Sintilimab, Monoclonal Antibody Against Programmed Cell Death-1, plus Chemotherapy in Patients with Advanced Non-Small-Cell Lung CancerLi Zhou, Yanjuan Xiong, Yang Wang, et al.The Lancet. Respiratory Medicine|December 7, 2025
First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, multicentre phase 3 trialLin Wang, Xuezhi Hao, Yanrong Hao, et al.Cancer Cell|April 17, 2014
Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasisWeiying Zhou, Miranda Y Fong, Yongfen Min, et al.Nature Cell Biology|January 27, 2015
Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasisMiranda Y Fong, Weiying Zhou, Liang Liu, et al.Cancer Communications (London, England)|June 12, 2026
Serplulimab Plus Chemotherapy, with or without HLX04, versus Chemotherapy as First-Line Treatment for Nonsquamous NSCLC: Final Survival Analysis of the Phase III ASTRUM-002 StudyXuezhi Hao, Lin Wang, Yanrong Hao, et al.Pageof 30